GeminIQ Website Logo

Viewing ARTV free

Subscribe for full history, 50+ metrics, screener, watchlist...

Artiva Biotherapeutics, Inc.

ARTV

Companies in Biological Products, (No Diagnostic Substances)

Artiva Biotherapeutics, Inc. (ARTV) — SEC Financial Statements & Analysis

Artiva Biotherapeutics, Inc. (ARTV) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
2127262830405634
Short Term Investments
6681971141361459112
Accounts Receivable Net Current
-----011
Other Receivables Net Current
-0000001
Prepaid Expense And Other Assets Current
25674332
Assets Current
8911313014917018915150
Restricted Cash Noncurrent
00000000
Property Plant And Equipment Net
67777677
Operating Lease Right Of Use Asset
1011111313141415
Finance Lease Right Of Use Asset
00000000
Deferred Costs
-------3
Long Term Investments
------53-
Other Assets Noncurrent
00000000
Assets
10613114916919121022676
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current
20112111
Accrued Liabilities Current
610766786
Operating Lease Liability Current
33344444
Finance Lease Liability Current
00000000
Other Liabilities Current
-0000---
Liabilities Current
1113111112121311
Operating Lease Liability Noncurrent
7891010111112
Finance Lease Liability Noncurrent
----0000
Derivative Liabilities Noncurrent
-------28
Other Liabilities Noncurrent
-----000
Liabilities
1821202022232551
Stockholders Equity
Common Stock Value
0000000-
Additional Paid In Capital Common Stock
44244043943743643343122
Accumulated Other Comprehensive Income Loss Net Of…
-0000--000
Retained Earnings Accumulated Deficit
-354-331-310-288-267-247-231-213
Stockholders Equity
88110129149169187201-191
Liabilities And Stockholders Equity
10613114916919121022676
Temporary Equity Par Or Stated Value Per Share
-------0
Preferred Stock Shares Authorized
-------10
Common Stock Par Or Stated Value Per Share
-------0
Common Stock Shares Authorized
-------700
Common Stock Shares Issued
0000000-

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-27.18%-11.66%----------
2025-11.47%-32.57%65.14%9.76%3.14%88.50%-15.58%6.28%-2.26%10.86%77.63%30.43%
2024---10.27%7.70%-10.97%-9.72%-18.36%-61.13%-42.71%-48.08%-49.36%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
8.16
8.61
11.65
13.84
13.93
15.39
11.33
4.59
Quick Ratio
7.98
8.26
11.07
13.22
13.62
15.15
11.08
4.43
Working Capital
77.86M
99.58M
118.41M
138.30M
157.80M
176.38M
137.27M
38.92M
Leverage & Debt
Debt to Equity
0.21
0.19
0.15
0.14
0.13
0.12
0.12
-0.26
Debt Ratio
0.17
0.16
0.13
0.12
0.12
0.11
0.11
0.67
Efficiency & Turnover
Asset Turnover TTM
0.00
0.00
0.00
0.00
0.00
-
-
-
Per Share Metrics
Diluted EPS TTM
-1.76
-1.72
-1.90
-1.83
-1.76
-
-
-
Free Cash Flow Per Share TTM
-1.62
-1.62
-1.61
-1.45
-1.56
-
-
-
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
-
-
-
Margin Metrics
Operating Profit Margin TTM
-
-
-
-38,276.10%
-17,819.32%
-
-
-
Net Profit Margin TTM
-
-
-
-35,496.02%
-17,068.53%
-
-
-
Growth Metrics
Net Revenue Growth (1Y)
-100.00%
-
-
-
-
-
-
-
Net Income Growth (1Y)
1.62%
-
-
-
-
-
-
-
EPS Growth (1Y)
0.23%
-
-
-
-
-
-
-
Valuation Metrics
P/E TTM
-3.65
-2.50
-1.51
-0.83
-1.70
-
-
-
P/B
3.62
1.91
1.09
0.49
0.87
2.43
2.91
-
P/S TTM
-
-
-
293.32
290.94
-
-
-
Market Cap
317.86M
209.73M
140.53M
73.62M
146.05M
453.96M
583.91M
-
Enterprise Value
296.45M
182.61M
114.63M
44.80M
115.33M
413.89M
527.97M
-
Calculated Values
Free Cash Flow TTM
-80.18M
-79.34M
-78.91M
-70.81M
-76.03M
-
-
-
Net Debt
-21.41M
-27.12M
-25.89M
-28.82M
-30.73M
-40.07M
-55.95M
-34.28M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-06-26Purchase
Owner: Ra, Capital Management, L…
Title: -
Shares: 1,876
Price/Share: $8.98
Value: $16,846.48
Shares Owned: 16,795,919
Relationship: Director,TenPercentOwner
Ownership: Indirect
2026-06-16Purchase
Owner: Kolchinsky, Peter, Ra Cap…
Title: -
Shares: 124,893
Price/Share: $8.89
Value: $1,110,298.77
Shares Owned: 16,763,043
Relationship: Director,TenPercentOwner
Ownership: Indirect
2026-06-11Purchase
Owner: Ra, Capital Nexus Fund, L…
Title: -
Shares: 548,580
Price/Share: $7.91
Value: $4,339,267.80
Shares Owned: 16,231,717
Relationship: Director,TenPercentOwner
Ownership: Indirect
2026-05-19Sale
Owner: Aslan, Fred
Title: Chief Executive Officer
Shares: 27,116
Price/Share: $9.01
Value: $244,315.16
Shares Owned: 1,535,082
Relationship: Director,Officer
Ownership: Direct
2026-05-19Sale
Owner: Horan, Christopher
Title: Chief Tech Operations Officer
Shares: 7,002
Price/Share: $9.01
Value: $63,088.02
Shares Owned: 293,450
Relationship: Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
34.11%
Inst. Shares: 16,834,243
Shares Outstanding: 49,356,840
2025-12-31
34.68%
Inst. Shares: 16,956,116
Shares Outstanding: 48,888,114
2025-09-30
37.02%
Inst. Shares: 18,125,838
Shares Outstanding: 48,963,444
2025-06-30
37.80%
Inst. Shares: 18,428,275
Shares Outstanding: 48,757,646
2025-03-31
42.86%
Inst. Shares: 20,864,108
Shares Outstanding: 48,683,956

Research Faster.
Invest Smarter.

Artiva Biotherapeutics, Inc. (ARTV) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.